DPP 4 INHIBITORS WHAT MAY BE THE CLINICAL DIFFERENTIATORS PDF

Attenuation of the prandial incretin effect, mediated by glucagon-like peptide-1 GLP-1 and glucose-dependent insulinotropic peptide GIP , contributes to hyperglycemia in type 2 diabetes mellitus T2DM. Since the launch of sitagliptin in , a compelling body of evidence has accumulated showing that dipeptidyl peptidase-4 DPP-4 inhibitors, which augment endogenous GLP-1 and GIP levels, represent an important advance in the management of T2DM. Currently, three DPP-4 inhibitors - sitagliptin, vildagliptin and saxagliptin - have been approved in various countries worldwide. Several other DPP-4 inhibitors, including linagliptin and alogliptin, are currently in clinical development. As understanding of, and experience with, the growing number of DPP-4 inhibitors broadens, increasing evidence suggests that the class may offer advantages over other antidiabetic drugs in particular patient populations.

Author:Tat Akisar
Country:Bulgaria
Language:English (Spanish)
Genre:Health and Food
Published (Last):20 April 2007
Pages:375
PDF File Size:16.85 Mb
ePub File Size:19.60 Mb
ISBN:375-4-31026-111-8
Downloads:86750
Price:Free* [*Free Regsitration Required]
Uploader:Mosida



Attenuation of the prandial incretin effect, mediated by glucagon-like peptide-1 GLP-1 and glucose-dependent insulinotropic peptide GIP , contributes to hyperglycemia in type 2 diabetes mellitus T2DM. Since the launch of sitagliptin in , a compelling body of evidence has accumulated showing that dipeptidyl peptidase-4 DPP-4 inhibitors, which augment endogenous GLP-1 and GIP levels, represent an important advance in the management of T2DM. Currently, three DPP-4 inhibitors - sitagliptin, vildagliptin and saxagliptin - have been approved in various countries worldwide.

Several other DPP-4 inhibitors, including linagliptin and alogliptin, are currently in clinical development. As understanding of, and experience with, the growing number of DPP-4 inhibitors broadens, increasing evidence suggests that the class may offer advantages over other antidiabetic drugs in particular patient populations.

The expanding evidence base also suggests that certain differences between DPP-4 inhibitors may prove to be clinically significant. This therapeutic diversity should help clinicians tailor treatment to the individual patient, thereby increasing the proportion that safely attain target HbA 1c levels, and reducing morbidity and mortality. This review offers an overview of DPP-4 inhibitors in T2DM and suggests some characteristics that may provide clinically relevant differentiators within this class.

All rights reserved. This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable.

Search: Search. Advanced Clipboard. Create file Cancel. Email citation To:. Format: Summary Summary text Abstract Abstract text. Send email Cancel. Add to Collections Create a new collection Add to an existing collection. Name your collection: Name must be less than characters. Choose a collection: Unable to load your collection due to an error Please try again. Add Cancel. Add to My Bibliography My Bibliography.

Unable to load your delegates due to an error Please try again. Your saved search Name of saved search:. Search terms:. Test search terms. Would you like email updates of new search results?

Email: change. Frequency: Monthly Weekly Daily. Which day? Send at most: 1 item 5 items 10 items 20 items 50 items items items. Send even when there aren't any new results.

Optional text in email:. Save Cancel. Create a file for external citation management software Create file Cancel. Full-text links Cite Favorites. Abstract Attenuation of the prandial incretin effect, mediated by glucagon-like peptide-1 GLP-1 and glucose-dependent insulinotropic peptide GIP , contributes to hyperglycemia in type 2 diabetes mellitus T2DM. Chen R, et al. Diabetes Res Clin Pract. Epub Apr 3. PMID: No abstract available. Similar articles DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.

Scheen AJ. Diabetes Metab. Epub Dec PMID: Review. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Bourdel-Marchasson I, et al. Hosp Pract Mechanism of action of inhibitors of dipeptidyl-peptidase-4 DPP Thornberry NA, Gallwitz B. Thornberry NA, et al. PMID: Ishikawa M, Yamada Y. Ishikawa M, et al. Nihon Rinsho. PMID: Japanese. No abstract available. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.

Show more similar articles See all similar articles. Gilbert MP, et al. Front Endocrinol Lausanne. Diabetes pharmacotherapy and effects on the musculoskeletal system. Kalaitzoglou E, et al. Diabetes Metab Res Rev. Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males. Sangle GV, et al. Eur J Clin Pharmacol. Epub Mar 6.

Aoki C, et al. Nagoya J Med Sci. Clinical Trial. Matsushima Y, et al. Show more "Cited by" articles See all "Cited by" articles. Publication types Review Actions. Energy Intake Actions. Humans Actions. Linagliptin Actions. Sitagliptin Phosphate Actions. Vildagliptin Actions. Substances Blood Glucose Actions. Dipeptides Actions.

Glycated Hemoglobin A Actions. Hypoglycemic Agents Actions. Incretins Actions. Nitriles Actions. Piperidines Actions. Purines Actions. Pyrazines Actions. Pyrrolidines Actions. Quinazolines Actions.

Triazoles Actions. Uracil Actions. Glucagon-Like Peptide 1 Actions. Dipeptidyl Peptidase 4 Actions. Adamantane Actions. Full-text links [x] Elsevier Science. Copy Download.

ASTANGA HRIDAYA IN PDF

DPP-4 Inhibitors: What May Be the Clinical Differentiators?

Skip to search form Skip to main content You are currently offline. Some features of the site may not work correctly. DOI: Gerich Published Medicine Diabetes research and clinical practice.

BURKHART ANTHOLOGY FOR MUSICAL ANALYSIS PDF

DPP-4 inhibitors: what may be the clinical differentiators?

.

THEORY OF MECHANISMS AND MACHINES BY AMITABHA GHOSH PDF

.

COMPANIESHOUSE GOV UK INFOANDGUIDE FAQ WEBFILINGUSERGUIDE PDF

.

Related Articles